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ABSTRACT
Background: Recent reports suggest that small airway as well as large airway involvement in asthma is im-
portant. We investigate the therapeutic effects of a meter-dose inhaler of chrolofluorocarbon-beclomethasone
dipropionate (CFC-BDP) and dry-powder fluticasone (DP-FP).
Methods: Lung specimens obtained at operation due for small size lung cancer in 16 asthmatic patients and
16 controls were evaluated immunohistochemically using antibodies of EG2 (eosinophil), AA1 (mast cell),
CD68 (macrophage), and CD34 (pluripotent hematopoietic stem cell). We calculated the number of each cell
type in 5 fields in the inner and outer areas of large airways (luminal diameter;2 mm) and small airways (<2
mm) using computer software.
Results: In asthmatic patients eosinophils were significantly increased in both inner and outer areas of small
airways and the number of CD34+ cells was significantly elevated in inner areas as compared with controls. Al-
though the density of eosinophils in the inner area of large airways was significantly suppressed (p < 0.02),
there was no such suppression in the inner areas of small airways in asthmatic patients treated with CFC-BDP
or DP-FP.
Conclusions: It was speculated that inhaled CFC-BDP and DP-FP might deposit mainly in large airways and
fail to fully reach small airways, consequently allowing eosinophilic inflammation to continue in small airways.
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INTRODUCTION
Asthma is characterized by eosinophil dominant
chronic inflammation throughout large and small air-
ways.1,2 However there have been no reports on the
therapeutic efficacy of current treatment with inhaled
corticosteroids (ICSs) on small airway inflammation.
In Japan between 1997 and 2002, three kinds of ICS
drugs were available ; dry-powder fluticasone (DP-
FP), dry-powder budesonide, meter-dose inhaler of
chlorofluorocarbon-beclomethasone ( CFC-BDP ) .
The International Commission on Radiological Pro-
tection has information on lung deposition, including
a good model of deposition efficiency as a function of
median particle size , and this model demonstrates
that the majority of particles ranging from 2.5 to 6 μm
in diameter are deposited in large airways,3 and those
under 2.5 μm are deposited mostly in the alveolar
area.4 In general, the smaller particles can reach the
more peripheral airways, but for an optimal therapeu-
tic response to ICSs the inhaled particles should
reach both large and small airways. The mass median
aerodynamic diameters (MMADs) of CFC-BDP and
DP-FP are between 2.5 to 6 μm, 5,6 and total lung
deposition rate of these two ICSs are between 10 to
20%. 4,7 Not all asthmatic patients return to normal
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Table 1 Subject characteristics
Asthma Control 
16 (12/4) 16 (11/5) No. (male/female)
 62.2 ± 2.5 62.3 ± 2.9 Age, yr
10/6 9/7 Smoking, yes/no
11 0 Treatment with ICS, yes
98.9 ± 6.2　96.9 ± 10.7VC, % predicted
 66.8 ± 2.9＊83.6 ± 3.9 FEV1/FVC ratio, %
84.7 ± 7.1　96.4 ± 8.0 FEV1, % predicted
48.9 ± 8.1 ＊80.0 ± 9.3 V50, % predicted
35.5 ± 5.6 ＊61.2 ± 3.1 V25, % predicted
Data are presented as mean ± SEM/mm2. ICS ＝ inhaled corticosteroid
＊p＜0.05 compared with control














T63.5 342 3 yrsyesM70
T, β252.0102712 yrsyesM74
T, β260.4 122 7 yrsnoF68
T, β2, BDP 800 μg/day70.0 679 4 yrsnoM68
ICS (＋)
n＝11
T, β2, FP 400 μg/day71.9 571 5 yrsyesM76
T, β2, FP 400 μg/day65.7NT514 yrsyesM70
T, β2, FP 400 μg/day68.0 3021 yryesM50
β2, BDP 400 μg/day53.0 16412 yrsnoF50
T, β2, BDP 400 μg/day41.9NT5 7 yrsyesM65
β2, FP 400 μg/day84.4 14211 yrsnoF76
β2, FP 800 μg/day60.33124 8 yrsyesM55
T, β2, BDP 800 μg/day80.715612 20 yrsyesM48
T, β2, BDP 800 μg/day66.7 54110 yrsnoF59
Salmeterol 100 μg/day, 
FP 400 μg/day
70.3 232 5 yrsyesM49
ICS: inhaled corticosteroid, Eo: peripheral blood eosinophil, NT: not tested 
T: slow-releasing theophyline, β2: inhaled β2-agonist 
BDP: chlorofluorocarbon-beclomethasone, FP: dry-powder fluticasone
lung function and airway hyperresponsiveness even
after intensive treatment with ICS andor β2-agonists.
A possibility exists that since most inhalation formula-
tions have particle sizes too large to reach the small
airways, we are not comprehensively treating the air-
way inflammation and bronchoconstriction . We
tested the hypothesis that there was a therapeutic
limitation for larger particle ICS in the treatment of
small airway disease in asthma . We examined the
therapeutic efficacy of CFC-BDP and DP-FP on
eosinophilic inflammation in small airways using sur-
gically resected lung specimens from asthmatic pa-
tients who had been treated with these ICSs.
METHODS
SUBJECTS
Thirty-two subjects were recruited from the Sapporo
Medical University Hospital and Minami Ichi-jo Hos-
pital. They underwent lobectomy or pneumonectomy
for small peripheral lung cancer between 1997 and
2002. Asthma was defined according to the criteria of
the American Thoracic Society,8 and the severity de-
fined by the Global Initiative for Asthma.9 The subject
characteristics are shown in Tables 1, 2. Sixteen con-
trol subjects who had no history of asthma were se-
lected from the same hospitals’ medical file between
1997 and 2002 on the basis of the best match to asth-
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Table 3 Inflammatory cels in smal airways in control and asthmatic patients
Asthma (n＝16)Control (n＝16)
outerinnerouterinnerArea
111.0 ± 14.1118.5 ± 20.095.9 ± 15.984.5 ± 16.1Mast cels
 8.4 ± 1.3 3.9 ± 4.15.9 ± 2.24.3 ± 1.5Macrophages
  103.9 ± 13.6＊   94.7 ± 24.5＊33.1 ± 23.912.3 ± 12.1Eosinophils
 65.7 ± 20.1  125.9 ± 9.5＊33.9 ± 7.1 42.4 ± 8.4 CD34 ＋cels
Mean ± SEM/mm2＊p＜0.05 compared with control
Table 4 Inflammatory cels in inner area of large and smal airways in asthmatics patients treated with or without inhaled 
corticosteroid
Asthmatic patients
p-valueICS (＋) n＝11ICS (－) n＝5
0.99 95.3 ± 13.2 98.9 ± 17.4Mast celsLarge airways 
0.79  9.1 ± 3.5 14.6 ± 6.8Macrophages
 0.013 36.1 ± 19.2173.4 ± 42.9Eosinophils
0.69 59.1 ± 8.9 73.2 ± 10.8CD34 ＋cels
0.29105.2 ± 18.9135.0 ± 20.0Mast celsSmal airways
0.34  1.4 ± 1.4   7.0 ± 4.1Macrophages
0.99100.4 ± 47.5 90.0 ± 44.9Eosinophils
0.93145.3 ± 39.0122.4 ± 9.5CD34 ＋cels
Mean ± SEM/mm2ICS; inhaled corticosteroid (CFC-BDP, DP-FP) 
matic patients with respect to age, sex and smoking
history . As shown in Table 2, eleven patients with
asthma were treated with CFC-BDP, 400―800 μgday
or DP-FP, 400―800 μgday and the other 5 patients
did not receive ICSs. There were no significant differ-
ences between the two groups in age, sex, tobacco
habit, asthma duration period or FEV1%. This study
was approved by the Sapporo Medical University eth-
ics committee, and written informed consent was ob-
tained from all subjects.
IMMUNOHISTOCHEMISTRY
Lung specimens without cancer were fixed with 10%
formalin and embedded in paraffin. Sections of 5 μm
thickness were deparaffinized with xylene , dehy-
drated in ethanol, and then heated in a domestic mi-
crowave oven (500 watts) for 5 minutes to retrieve an-
tigens. Endogenous peroxidase was blocked by incu-
bation in 1% hydrogen peroxide in methanol for 30
minutes. After washing with phosphate-buffered sa-
line (PBS), they were incubated with 2% normal anti-
bodies for 30 minutes at room temperature . Anti-
CD34 monoclonal antibody (Becton Dickinson Im-
munocytometry Systems, San Jose, USA), anti-CD68
monoclonal antibody (NEO MARKERS , Fremont ,
USA) , anti-tryptase monoclonal antibody (DAKO ,
Glostrup, Denmark) , anti-tryptase monoclonal anti-
body (DAKO, Glostrup , Denmark) , and anti-EG2
monoclonal antibody (Pharmacia&Upjohn, Peapack,
USA) were used . They were incubated with bioti-
nylated anti-mouse or rabbit immunoglobulin G (IgG,
heavy and light chains H&L) affinity purified anti-
body for 30 minutes, followed by incubation with the
Vectastain Elite ABC kit (Vector Laboratories, Burl-
ingame, CA, USA) for 30 minutes. They were washed
3 times with PBS for 5 minutes each and immersed in
a 0.05% diaminobenzidine tetrahydrochloride solution
containing 0.03% hydrogen peroxide for 1―3 minutes
followed by counterstaining of the nuclei with hema-
toxylin solution . Normal mouse Ig was used as a
negative control. Two observers who had no knowl-
edge of the subject characteristics counted each in-
flammatory cell, and each observer examined 5 fields
for each patient. The mean coefficient of variation for
repeated measurements was 6―10% for each inflam-
matory cell.
AIRWAY CLASSIFICATION
Small airways were defined as membranous airways
with an inner diameter < 2 mm without cartilage .
Large airways were defined as airway tissue that con-
tained cartilage with an inner diameter of
2―5 mm.10,11
QUANTITATION
Each subject was examined in 5 fields each consist-
ing of medium and small airways. The vascularity and
number of cells was counted separately in the inner
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Fig. 1 The number of eosinophils in the inner and outer 
area of large and smal airways in asthmatic patients treated 
with or without inhaled corticosteroids (ICS). Eosinophil infil-
tration in the inner area of large airways is significantly sup-
pressed by ICS therapy, but is not inhibited in the inner area 
of smal airways.
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airway wall between the basement membrane and the
outer border of smooth muscle and in the outer wall
between the outer border of the smooth muscle and
the parenchyma 2,11 excluding mucous glands ,
smooth muscle and cartilage. The number of each in-
flammatory cell per mm2 was examined using a light
microscope with MOTIC 2000 (Shimazu Rikaki, To-
kyo Japan ) software . Two observers who had no
knowledge of the subject characteristics counted the
vessels, and each observer examined 5 fields for each
patient. The mean coefficient of variation for repeated
measurements was 6―10% for each inflammatory cell.
DATA ANALYSIS
The values are presented as mean ± SEM. The Mann-
Whitney and χ2 tests were used for comparison be-
tween the two groups. A p value of less than 0.05 was
considered statistically significant.
RESULTS
The number of eosinophils in the inner and outer
area of small airways was significantly (p < 0.05) in-
creased in asthmatics and the number of CD34+cells
in the inner area of small airways was significantly
(p < 0.05) elevated as compared with those of con-
trols (Table 3). The mean number of eosinophils in
the outer area of small airways was higher than that
in the inner area, but there was no significant differ-
ence. On the other hand, in large airways of asthmat-
ics, the number of both eosinophils and CD34+ cell in
the inner area were significantly (p < 0.05) higher
than those in controls (18.3 mm2 ± 10.2 vs 89.4 ±
19.5, 38.4mm2 ± 7.2 vs 98.4 ± 19.5, respectively). No
differences were observed in the number of mast
cells and macrophages in either small or large air-
ways between asthma patients and controls.
Although the cell density of eosinophils in the in-
ner area of large airways was significantly suppressed
(p < 0.02) in asthmatic patients treated with CFC-BDP
or DP-FP as compared with patients without ICS
treatment, there was no such suppression in the in-
ner area of small airways (Table 4, Fig. 1). In the case
of mast cells, macrophages, and CD34+ cells, there
was no suppression by ICS therapy in either small or
large airways (Table 4).
DISCUSSION
Our results demonstrated that eosinophils and
CD34+ cells in small airways were significantly in-
creased in asthmatic patients as compared with con-
trols. However mast cells and macrophages were not
increased. The CD34 molecule is expressed on pluri-
potent hematopoietic stem cells as well as on eosino-
phils, monocytesmacrophages and subsets of lym-
phocytes , and CD 34 + stem cells also express
cysteinyl-leukotriene receptor 1 and 2, which differ-
entiate to various inflammatory cells and enhance
asthmatic inflammation. Many investigators have re-
ported inflammatory changes in the small airways in
subjects with asthma using lung specimens. 2,10,12,13
Saetta et al. 13 found evidence of increased mucus
plugging, airway smooth muscle thickening, and infil-
tration of inflammatory cells including eosinophils in
the small airways in fatal asthma patients . Hamid
et al. 2 observed that inflammatory changes were
more severe in small airways than in large airways of
asthmatic patients who had undergone lung resection
for tumor. Kraft et al.14 reported that eosinophilic in-
flammation in nocturnal asthma was greater in pe-
ripheral tissue than in the large bronchi in the early
morning hours.
Other studies have shown that , unlike large air-
ways, inflammatory cell infiltration predominates in
the outer area of small airways.15-17 In our study, in-
flammatory cell density in small airways was not in-
creased in outer areas compared with inner areas .
Hamid et al. 2 reported a greater number of total
eosinophils in the outer layer compared with the in-
ner layer in small airways. It has also been reported
that outer area inflammation16 and destruction of al-
veolar attachment18 were more prominent in patients
with severe asthma , but in our cases the results
showed more prominence in mild and moderate
asthma patients. This may be one of the reasons why
outer area inflammation was not predominant in the
present study.
The density of eosinophils in the inner area of
large airways was significantly suppressed (p < 0.02),
but this suppression of eosinophils was not seen in
the inner area of small airways in patients with
asthma treated with CFC-BDP or DPI-FP. Hauber et
al.19 reported that HFA-flunisolide (MMAR is 1.2 μm)
effectively suppressed eosinophilic airway inflamma-
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tion in both small and large airways using trans-
bronchial biopsy specimens. It was speculated that
the particle size of CFC-BDP and DP-FP prevented
them from reaching small airways.
In conclusion, ICSs of CFC-BDP (400―800 μgday)
or DP-FP ( 400 ― 800 μgday ) markedly reduced
eosinophils in large airways, but not in small airways
in resected lung specimens of patients with bronchial
asthma. Lung deposition rate of ICSs to small airways
might be one of the important factors in the treat-
ment of bronchial asthma.
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